Skip to main content

Table 1 Basic characteristics of HIV positive subjects

From: Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

Characteristics

ZOL(−) (N = 38)

ZOL(+) (N = 36)

P value

Age, year

41.2 ± 6.8

40.8 ± 5.6

0.331

Sex, male (%)

31 (81.6)

30 (83.3)

0.324

Race

  

0.520

 White

13 (34.2)

12 (33.3)

 

 Black

25 (65.8)

24 (66.7)

 

History of smoking

  

0.421

 Yes

31 (81.6)

31 (86.1)

 

 No

7 (18.4)

5 (13.9)

 

Current smoking

  

0.699

 Yes

29 (76.3)

30 (83.3)

 

 No

9 (23.7)

6 (16.7)

 

Cigarettes smoked per day (in patients with history of smoking)

3 (7.9)

3 (8.3)

0.383

Years of cigarette smoking (in patients with history of smoking)

3 (7.9)

4 (11.1 + G14:N14)

0.349

History of bone fracture

  

0.636

 Yes

8 (21.1)

5 (13.9)

 

 No

30 (78.9)

31 (86.1)

 

HIV RNA, log10 copies/mL (SD)

4.1 ± 0.8

3.7 ± 0.7

0.536

CD4 count, cells/uL (SD)

159.7 ± 37.7

153.3 ± 44.9

0.498

Serum calcium, mg/dL(SD)

9.8 ± 3.8

9.7 ± 2.6

0.568

Serum vitamin D, ng/mL(SD)

24.9 ± 6.1

24.3 ± 5.7

0.430